As of 13:43 on April 1, 2025, the Shanghai Stock Exchange Science and Technology Innovation Board Biomedical Index (000683) rose 3.85%, the constituent stocks Bio-Thera (688177) rose 9.99%, Mabwell (688062) rose 9.76%, Microelectrophysiology (688351) rose 8.06%, and Weigao Orthopedics (688161), Yifang Biotech (688382) and other stocks followed suit. Kechuang Biomedical ETF (588250) rose 3.22%, with an intraday turnover of 154 million yuan and a turnover rate of 34.81%, and the market was actively traded.

The SSE Sci-Tech Innovation Board Biomedical Index selects 50 securities of listed companies in the fields of biomedicine, biomedical engineering, bioagriculture, biomass energy, and other biological industries with large market capitalization from the STAR Market as index samples, reflecting the overall performance of the securities of listed companies in the representative biomedical industry in the STAR Market.

On the news side, according to Artery.com, the amount and number of license-out transactions of China's innovative pharmaceutical companies in 2024 will reach a new high, with a total down payment of US$3.16 billion from January to October 2024, exceeding the R&D financing of innovative drugs by US$2.71 billion in the first year, and the amount of down payments for many transactions is eye-catching. According to incomplete statistics, from January to October 2024, a total of 76 license-out transactions occurred in the field of innovative drugs in China. In terms of transaction value, the down payment amount of license-out transactions from January to October 2024 was approximately US$3.16 billion, and the total transaction value reached US$51.1 billion, exceeding the total amount of license-out transactions in 2023.

Shanghai Securities believes that favorable policies in the field of innovative drugs continue to be introduced, and the number of new drugs approved has reached a new high. In 2024, the performance of many sector enterprises will recover and gradually enter the harvest period, the license-out transaction model will continue to be hot, and the pace of industry development is expected to accelerate.

According to the data, as of March 31, 2025, the top 10 weighted stocks in the SSE Science and Technology Innovation Board Biomedical Index (000683) are United Imaging Medical (688271), BeiGene (688235), Huitai Medical (688617), Allist (688578), Baili Tianheng (688506), Zelgen Pharmaceutical (688266), MGI (688114), Junshi Biosciences (688180), Aibo Medical (688050), Tebao Biotechnology (688278), the top ten weighted stocks accounted for 51.35% of the total.